Anti-idiotypic antibody specific to GAD65 autoantibody prevents type 1 diabetes in the NOD mouse

PLoS ONE

Volumn 7, Issue 2, 2012, Pages

  Wang, Xin ^a   Zhang, Aixia ^b   Liu, Yu ^c   Chen, Shi ^a   Feng, Zhenqing ^b   Shang, Wenbin ^d   Maziarz, Marlena ^e   Radtke, Jared ^e   Hampe, Christiane S ^e  

^a AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^d NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 8E6G4; MONOCLONAL ANTIBODY GAD65 B 96.11; UNCLASSIFIED DRUG; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; ISOPROTEIN;

ADOLESCENT; ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ARTICLE; BINDING COMPETITION; CELL INFILTRATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; NONOBESE DIABETIC MOUSE; NUCLEOTIDE SEQUENCE; PANCREAS ISLET CELL; RADIOASSAY; SCHOOL CHILD; SEQUENCE ANALYSIS; ANIMAL; BAGG ALBINO MOUSE; BINDING SITE; CHEMISTRY; DISEASE MODEL; DNA SEQUENCE; GENETICS; IMMUNOLOGY; MALE; MIDDLE AGED; PHYSIOLOGY;

ANIMALIA; MUS;

ADULT; AGED; ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; BINDING SITES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED NOD; MIDDLE AGED; PROTEIN ISOFORMS; SEQUENCE ANALYSIS, DNA;

EID: 84863165531     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0032515     Document Type: Article

References (44)

1. Sanjeevi CB, Falorni A, Robertson J, Lernmark A, (1996) Glutamic acid decarboxylase (GAD) in insulin-dependent diabetes mellitus. Diabetes Nutrition & Metabolism 9: 167-182.
2. Oak S, Gilliam LK, Landin-Olsson M, Torn C, Kockum I, et al. (2008) The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A 105: 5471-5476.
3. Jerne NK, (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C: 373-389.
4. Anderson CJ, Neas BR, Pan Z, Taylor-Albert E, Reichlin M, et al. (1998) The presence of masked antiribosomal P autoantibodies in healthy children. Arthritis Rheum 41: 33-40.
5. Stafford HA, Anderson CJ, Reichlin M, (1995) Unmasking of anti-ribosomal P autoantibodies in healthy individuals. J Immunol 155: 2754-2761.
6. Pan ZJ, Anderson CJ, Stafford HA, (1998) Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults. J Clin Invest 102: 215-222.
7. Williams WM, Isenberg DA, (1998) Naturally occurring anti-idiotypic antibodies reactive with anti-DNA antibodies in systemic lupus erythematosus. Lupus 7: 164-175.
8. Dwyer DS, Bradley RJ, Urquhart CK, Kearney JF, (1983) Naturally occurring anti-idiotypic antibodies in myasthenia gravis patients. Nature 301: 611-614.
9. Routsias JG, Dotsika E, Touloupi E, Papamattheou M, Sakarellos C, et al. (2003) Idiotype-anti-idiotype circuit in non-autoimmune mice after immunization with the epitope and complementary epitope 289-308aa of La/SSB: implications for the maintenance and perpetuation of the anti-La/SSB response. J Autoimmun 21: 17-26.
10. Sikorska HM, (1986) Anti-thyroglobulin anti-idiotypic antibodies in sera of patients with Hashimoto's thyroiditis and Graves' disease. J Immunol 137: 3786-3795.
11. Abdou NI, Suenaga R, Hatfield M, Evans M, Hassanein KM, (1989) Antiidiotypic antibodies against anti-DNA antibodies in sera of families of lupus patients. J Clin Immunol 9: 16-21.
12. Abdou NI, Wall H, Lindsley HB, Halsey JF, Suzuki T, (1981) Network theory in autoimmunity. In vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J Clin Invest 67: 1297-1304.
13. Taniguchi O, Chia DS, Barnett EV, (1984) Auto-anti-anti-DNA antibodies from SLE patients and normals. J Rheumatol 11: 291-297.
14. Zouali M, Eyquem A, (1983) Expression of anti-idiotypic clones against auto-anti-DNA antibodies in normal individuals. Cell Immunol 76: 137-147.
15. Silvestris F, Bankhurst AD, Searles RP, Williams RC Jr, (1984) Studies of anti-F(ab′)2 antibodies and possible immunologic control mechanisms in systemic lupus erythematosus. Arthritis Rheum 27: 1387-1396.
16. Williams RC Jr, Malone CC, Huffman GR, Silvestris F, Croker BP, et al. (1995) Active systemic lupus erythematosus is associated with depletion of the natural generic anti-idiotype (anti-F(ab′)2) system. J Rheumatol 22: 1075-1085.
17. Paschke R, Teuber J, Enger I, Schmeidl R, Schwedes U, et al. (1990) Evidence for a role of anti-idiotypic antibodies in the induction of remission in Graves' disease. J Autoimmun 3: 441-448.
18. Tada H, Izumi Y, Watanabe Y, Takano T, Fukata S, et al. (2001) Blocking type anti-tSH receptor antibodies detected by radioreceptor assay in Graves' disease. Endocr J 48: 703-710.
19. Sapir T, Shoenfeld Y, (2005) Facing the enigma of immunomodulatory effects of intravenous immunoglobulin. Clin Rev Allergy Immunol 29: 185-199.
20. Hall TR, Bogdani M, Leboeuf RC, Kirk EA, Maziarz M, et al. (2008) Modulation of diabetes in NOD mice by GAD65-specific monoclonal antibodies is epitope specific and accompanied by anti-idiotypic antibodies. Immunology 123: 547-554.
21. Nilson BH, Solomon A, Bjorck L, Akerstrom B, (1992) Protein L from Peptostreptococcus magnus binds to the kappa light chain variable domain. J Biol Chem 267: 2234-2239.
22. Brooks-Worrell B, Palmer JP, (2012) Immunology in the Clinic Review Series; focus on metabolic diseases: development of islet autoimmune disease in type 2 diabetes patients: potential sequelae of chronic inflammation. Clin Exp Immunol 167: 40-46.
23. Atkinson MA, Leiter EH, (1999) The NOD mouse model of type 1 diabetes: as good as it gets? Nat Med 5: 601-604.
24. Bach JF, (2002) Immunotherapy of type 1 diabetes: lessons for other autoimmune diseases. Arthritis Res 4 (Suppl 3): S3-15.
25. Aly T, Devendra D, Eisenbarth GS, (2005) Immunotherapeutic approaches to prevent, ameliorate, and cure type 1 diabetes. Am J Ther 12: 481-490.
26. Goudy KS, Tisch R, (2005) Immunotherapy for the prevention and treatment of type 1 diabetes. Int Rev Immunol 24: 307-326.
27. Ertl HC, Bona CA, (1988) Criteria to define anti-idiotypic antibodies carrying the internal image of an antigen. Vaccine 6: 80-84.
28. Valderrama R, Eggers AE, Revan S, Moomjy M, Frost M, et al. (1988) Idiotypic control of the immune response. J Neuroimmunol 20: 269-276.
29. Knip M, Siljander H, (2008) Autoimmune mechanisms in type 1 diabetes. Autoimmun Rev 7: 550-557.
30. Harbers SO, Crocker A, Catalano G, D'Agati V, Jung S, et al. (2007) Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance. J Clin Invest 117: 1361-1369.
31. O'Neill SK, Liu E, Cambier JC, (2009) Change you can B(cell)eive in: recent progress confirms a critical role for B cells in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 16: 293-298.
32. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, et al. (2009) Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 361: 2143-2152.
33. Usuki S, Taguchi K, Thompson SA, Chapman PB, Yu RK, (2010) Novel anti-idiotype antibody therapy for lipooligosaccharide-induced experimental autoimmune neuritis: use relevant to Guillain-Barre syndrome. J Neurosci Res 88: 1651-1663.
34. Kim J, Richter W, Aanstoot H-J, Shi Y, Fu Q, et al. (1993) Differential expression of GAD65 and GAD67 in human, rat, and mouse pancreatic islets. Diabetes 42: 1799-1808.
35. Quinn A, Sercarz EE, (1996) T cells with multiple fine specificities are used by non-obese diabetic (NOD) mice in the response to GAD(524-543). J Autoimmun 9: 365-370.
36. Zekzer D, Wong FS, Ayalon O, Millet I, Altieri M, et al. (1998) GAD-reactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 101: 68-73.
37. Falcone M, Lee J, Patstone G, Yeung B, Sarvetnick N, (1998) B lymphocytes are crucial antigen-presenting cells in the pathogenic autoimmune response to GAD65 antigen in nonobese diabetic mice. J Immunol 161: 1163-1168.
38. Serreze DV, Fleming SA, Chapman HD, Richard SD, Leiter EH, et al. (1998) B lymphocytes are critical antigen-presenting cells for the initiation of T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Immunol 161: 3912-3918.
39. Silveira PA, Johnson E, Chapman HD, Bui T, Tisch RM, et al. (2002) The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol 32: 3657-3666.
40. Tremble J, Morgenthaler NG, Vlug A, Powers AC, Christie MR, et al. (1997) Human B cells secreting immunoglobulin G to glutamic acid decarboxylase- 65 from a nondiabetic patient with multiple autoantibodies and Graves' disease: a comparison with those present in type 1 diabetes. J Clin Endocrinol Metab 82: 2664-2670.
41. Padoa CJ, Banga JP, Madec AM, Ziegler M, Schlosser M, et al. (2003) Recombinant Fabs of human monoclonal antibodies specific to the middle epitope of GAD65 inhibit type 1 diabetes-specific GAD65Abs. Diabetes 52: 2689-2695.
42. Raju R, Foote J, Banga JP, Hall TR, Padoa CJ, et al. (2005) Analysis of GAD65 Autoantibodies in Stiff-Person Syndrome Patients. J Immunol 175: 7755-7762.
43. Hampe CS, Lundgren P, T.L. D, Hammerle LP, Marcovina SM, et al. (2001) A Novel Monoclonal Antibody Specific for the N-Terminal End of GAD65. J Neuroimmunology 113: 63-71.
44. Hampe CS, Hammerle LP, Bekris L, Ortqvist E, Kockum I, et al. (2000) Recognition of Glutamic Acid Decarboxylase (GAD) by Autoantibodies from Different GAD Antibody-Positive Phenotypes. J Clin Endocrinol Metab 85: 4671-4679.